Efficacy of imatinib maintenance after stem cell transplantation for Ph+/ BCR:: ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease
{{output}}
Tyrosine kinase inhibitors are recommended as maintenance therapy following allogeneic stem cell transplantation (HSCT) for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), but optimal medication, dose, and duration remain a subject o... ...
